Status: Recruiting
GPC2-CAR T Cell Therapy for Relapsed or Refractory Medulloblastoma in Children and Young Adults
This is a single-site, open-label Phase I treatment study evaluating the manufacturing feasibility and safety of chimeric antigen receptor (CAR) T cells targeting the oncofetal protein Glypican-2 (GPC2) in pediatric and young adult patients with recurrent or refractory (R/R) medulloblastoma. Subjects with other non-medulloblastoma CNS embryonal tumors may enroll.
Participants needed: 18
Trial details
Phase: Phase 1Age: 1-30Biological sex: AllType: InterventionalSponsor: Stanford UniversityUpdated: Oct 9, 2026Locations: 1
Eligibility criteria
Diagnosis: Histologically confirmed diagnosis of medulloblastoma or other primar... [+29]
Any patient with metastatic disease OUTSIDE the CNS. [+12]